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Gentamicin Pharmacokinetics in Term Neonates 
Receiving Extracorporeal Membrane Oxygenation 
Varsha Bhatt-Mehta, Pharm.D., Cary E. Johnson, Pharm.D., and Robert E. Schumacher, M.D. 
Extracorporeal membrane oxygenation (ECMO) may affect the pharmacokinetics 
of certain drugs. The objectives of this study were to determine (1) the 
pharmacokinetics of gentamicin in neonates on ECMO and compare them to 
reported values for a similar patient population not on ECMO, (2) i f  the 
pharmacokinetics of gentamicin differ between venous-venous and venous- 
arterial bypass, and (3) if the pharmacokinetics of gentamicin are affected by 
oxygenator surface area (0.6 m’ vs 0.8 m’ oxygenators). The medical records of 
29 term neonates who received gentamicin while on ECMO were reviewed. 
Data col lected included gentamicin dosage, peak and trough serum 
concentrations determined at steady state, duration of treatment, time on ECMO, 
daily weights, and pertinent laboratory values. An initial dosage of gentamicin 
2.5 mg/kg every 18 hours is suggested for term neonates on ECMO. Dosage 
adjustments should be based on gentamicin serum concentrations, and 
modifications may also be required after ECMO. 
(Pharmacotherapy 1992;12(1):2&32) 
Extracorporeal membrane oxygenation (ECMO) 
involves the use of prolonged cardiopulmonary 
bypass in neonates with severe respiratory failure. 
This allows for a period of lung rest and recovery 
without the potentially damaging complications 
associated with prolonged mechanical ventilation, 
and is considered life saving for infants at high risk 
of dying from respiratory failure (Figure l ) . ’  Since 
the technique was pioneered in the mid-l970s, 
more than 4000 infants have received ECMO for 
respiratory failure. At present, approximately 1000 
patients are being added to the National Registry 
in Ann Arbor, Michigan, each year.* 
Several ECMO-related factors can theoretically 
affect the pharmacokinetics of certain drugs. The 
ECMO circuit presents a large surface area for 
adsorption of drugs onto a foreign surface, 
theoretically increasing the volume of drug 
distribution and reducing the bioavailability of the 
first dose. Three different sizes of membrane 
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oxygenators are used in newborns (0.4, 0.6, 0.8 
m’); the one used is primarily dependent on the 
size of the specific patient. The ECMO circuit is 
primed with approximately 400 ml blood, which 
exceeds the blood volume of most ful l- term 
neonates3 and may increase the volume of 
distribution of a drug. 
The ECMO circuit is most commonly introduced 
by venoarterial (V-A) bypass. In this technique 
oxygenated blood is delivered to the aorta through 
combined output of the mechanical pump and left 
ventricle. Total delivery is fixed by preload; 
however, at high pump flow rates, left ventricle 
output is minimal and nonpulsatile blood flow can 
result. Kidney function can be altered by changes 
in renal blood flow patterns. Nonpulsatile flow 
decreases urine output and sodium excretion in 
the absence of significant changes in mean arterial 
pressure, renal blood flow, or glomerular filtration 
This flow pattern could potentially affect 
drugs that are eliminated primarily by the renal 
route. 
Patients on ECMO often have drastic changes in 
total body water,’ presumably extracellular water, 
which may also increase the volume of distribution 
of a drug. The fluid overload that occurs during 
ECMO may require the use of hemofiltration in 
some infants. In addition to water, the hemofilter is 
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Table 1. Pharmacokinetic Data for Patients on V-A Bypass 
Pharmacokinetic Values 
Oxygenator K, Half-life vd TBC 
Diagnosis (m*) (hr-1) (hrs) (Likg) (Lihr) 
PPHN, RDS 
MA, RDS 
Fetal distress 
MA, Ebstein anomaly 
MA, RDS, PPHN 
RDS, congenital anomaly 
DH, RDS 
DH, RDS 
MA, RDS 
DH 
Sepsis 
RDS, sepsis 
RDS, DH 
RDS, MA, sepsis 
RiO'sepsis 
DH, RiO sepsis 
Mean 
0.8 
0.6 
0.6 
0.8 
0.8 
0.8 
0.8 
0.8 
0.6 
0.8 
0.6 
0.6 
0.8 
0.8 
0.8 
0.8 
0.08 8.7 0.81 
0.05 13.9 0.78 
0.07 9.8 0.73 
0.05 13.9 0.66 
0.1 1 6.3 0.39 
0.07 9.9 0.47 
0.06 11.6 0.59 
0.08 8.7 0.66 
0.07 9.9 0.73 
0.06 11.6 0.74 
0.08 8.7 0.48 
0.06 11.6 0.74 
0.08 8.7 0.48 
0.1 2 5.8 0.46 
0.05 13.9 0.70 
0.09 7.7 0.37 
0.074 10.04 0.61 
0.249 
0.121 
0.156 
0.121 
0.1 29 
0.1 25 
0.1 22 
0.1 95 
0.1 66 
0.1 69 
0.1 93 
0.1 17 
0.1 15 
0.249 
0.1 71 
0.1 10 
0.1 57 
?S D 0.02 2.45 0.1 5 0.046 
~ 
PPHN = persistent pulmonary hypertension of the newborn, RDS = respiratory distress syndrome, 
MA = meconium aspiration, DH = diaphragmatic hernia, R/O = rule out 
capable of removing most drugs with molecular 
weights less than 5200 daltons,' and therefore 
could increase drug clearance. 
Gentamicin, a commonly used antibiotic for the 
treatment of neonatal sepsis, is an example of a 
drug whose volume of distribution and clearance 
could be significantly changed by any or all of 
these factors. Therefore, the objectives of this 
retrospective study were to determine the 
l i i  C J I  
Figure 1. Schematic diagram of the extracorporeal 
membrane oxygenation circuit. 
el imination rate constant (Kel ) ,  volume of 
distribution (Vd), total body clearance (TBC), and 
elimination half-life of gentamicin in newborn 
infants receiving ECMO and compare these values 
to a non-ECMO populat ion of comparable 
gestational age; to identify the potential differences 
in the drug's pharmacokinetics between groups 
receiving ECMO by V-A and venovenous (V-V) 
bypass; and to identify potential differences in the 
pharmacokinetics of gentamicin in patients on 
oxygenators measuring 0.6 m' versus 0.8 m', 
which are most commonly used in our nursery. 
Methods 
The most frequently used ECMO circuit  
consisted of arterial and venous cannulas, 
extracorporeal tubing, venous reservoir, membrane 
oxygenator (SciMed; SciMed Life Systems, Inc., 
Minneapolis, MN), and heat exchanger 
(Ecmotherm; SciMed Life Systems, Inc.). If a 
hemofilter was required in the circuit, it was either 
a Minifilter or Minifilter Plus (W.R. Grace,.Danvers, 
MA). 
Data Collection 
Medical records of all neonates who received 
V-V or V-A ECMO between July 1988 and 
December 1989 were reviewed. Based on 
detecting a 20% difference in gentamicin 
pharmacokinetics between these patients and the 
values reported in the l iterature for full-term 
neonates, a minimum sample of 26 patients was 
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Table 2. Pharmacokinetic Data for Patients on V-V Bypass 
Pharmacokinetic Values 
Oxygenator K, Half-life “d TBC 
Diagnosis (m2) (hr-l) (hrs) Likg (Uhr) 
RDS pneumonia 0.8 0.09 7.7 0.69 0.210 
PFC, MA, pneumonia 0.8 0.06 11.4 0.80 0.1 80 
PFC, RDS, TTN 0.8 0.07 9.9 0.52 0.1 62 
PFC. MA, RDS 0.6 0.1 1 6.3 1.10 0.370 
MA 0.8 0.07 9.9 0.97 0.290 
PPHN, MA 0.8 0.10 6.9 0.71 0.254 
RDS, RiO sepsis 0.8 0.07 10.0 0.94 0.239 
DH, RDS 0.8 0.04 17.3 0.63 0.083 
RDS, RiO sepsis 0.8 0.04 17.3 0.45 0.063 
RDS, RiO sepsis 0.8 0.05 13.9 0.44 0.095 
RDS, sepsis 0.8 0.07 9.9 0.60 0.225 
MA, ?RDS 0.6 0.09 7.7 0.57 0.189 
Sepsis, pneumonia 0.8 0.06 11.6 1.17 0.229 
Mean 0.071 10.75 0.74 0.199 
k SD 0.022 3.43 0.23 0.086 
RDS = respiratory distress syndrome; PFC = persistent fetal circulation; MA = meconium 
aspiration; PPHN = persistent pulmonary hypertension of the newborn; 
DH = diaphragmatic hernia; TTN = transient tachypnea of the newborn; 
RiO = rule out. 
determined to be required.’-” A total of 68 
patients receiving ECMO were reviewed, of whom 
29 were included in the final data analysis. The 
others were not included due to uncertainty of 
blood sampling times in relation to dose or steady- 
state conditions, or their being preterm ( ~ 3 6  wks 
gestational age). 
The information collected from the medical 
records included patient demographics; diagnosis; 
gentamicin dosage; sampling times for peak and 
trough concentrations; duration of treatment with 
gentamicin; total time spent on ECMO; results of 
renal function tests including urine output, blood 
urea nitrogen, and serum creatinine; and daily 
weights during gentamicin therapy. Gentamicin 
serum samples were considered appropriate 
based on charting times if blood for the trough 
concentrations was obtained 0-1 5 minutes before 
the start of the next infusion and for the peak 
concentrations 30 minutes after a 30-minute 
infusion. All serum concentrations were measured 
after a minimum of four doses on a 12-hour dosing 
interval. 
Gentamicin was administered over 30 minutes 
into the ECMO circuit using a syringe pump. The 
site of administration was generally a port proximal 
to the venous blood reservoir. The gentamicin 
dosage for all infants included in the study was 2.5 
mg/kg based on birth weight, given every 12 hours 
initially. If required, dosage adjustments were 
made based on the first set of serum concen- 
trations measured at steady state on ECMO. 
Repeat concentrations were generally not 
obtained. The concentrations were determined by 
TDx fluorescent polarization immunoassay (Abbott 
Laboratories, Abbott Park, IL). The interday 
coefficient of variation for this assay over the range 
of concentrations determined in the study was less 
than 5%. 
Data Analysis 
calculated using the following standard equations: 
The pharmacokinetics of gentamicin were 
KeI = lnCl - InC2/ t2 - t ,  
ti,, = 0.693 I Ke, 
(dose/tjnf) . (1 - e-Ke’finf) 
Vd= TBC/Ke, 
where K, is the elimination rate constant, t,,2 is 
the half-life, V, is the volume of distribution, TBC is 
the total body clearance of gentamicin, Cpss is the 
steady-state gentamicin peak concentration, fjnr is 
the time of infusion, T is the dosing interval, and t2 
is the time from the end of infusion to when the 
peak was drawn. 
The data were stratified to group patients by type 
of bypass, V-A or V-V, and by size of oxygenator, 
0.6 or 0.8 m‘. The mean pharmacokinetics of 
gentamicin in each group were then compared 
using Student’s t test. A p value of less than 0.05 
was required for significance. Since only two point 
serum concentration-time data were available, it 
was not possible to  evaluate the data using 
compartmental modeling methods. 
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Table 3. Comparison (mean k SD) of Gentamicin Pharmacokinetics in Patients on V-A 
vs V-V Bypass and on 0.6 m2 vs 0.8 m2 Oxygenator 
K,I Half-life “d TBC 
No. of Pts (hr-’) (hrs) (ml) (Lihr) 
Bypass Type 
v- A 16 0.074k0.02 10.04F2.45 0.61 f 0 . 1 5  0.157i0.046 
v-v 13 0.071 kO.02 10.75k3.43 0.74k0.23 0.199FO.086 
p value > 0.05 >0.05 >0.05 >0.05 
0.6 m2 7 0.076k 0.02 9.70 k 2.51 0.730 k 0.195 0.187 f 0.086 
0.8 m2 22 0.071 k0 .02  10.57k3.17 0.648k0.2 0.172k0.064 
P value >0.05 >0.05 >0.05 >0.05 
Oxygenator 
Results 
The primary diagnosis of the 29 infants in the 
study included one or more of fol lowing: 
meconium aspiration syndrome, pneumonia, 
diaphragmatic hernia, sepsis, and respiratory 
distress syndrome. Mean (?SD) gestational age 
and birth weight were 39.2 f 2.7 weeks and 3.35 f 
0.71 kg, respectively. Serum creatinine concen- 
trations ranged from 0.3-2.4 mg/dl and blood urea 
nitrogen from 5-66 mg/dl. Urine output during the 
course of gentamicin therapy ranged from 0-7.9 
ml/kg/hour. Pharmacokinetic data as well as 
information on type of bypass and oxygenator size 
are shown in Tables 1 and 2. 
The calculated pharmacokinetics (mean k SD) 
for all 29 patients were as follows: k, 0.072 f 0.02 
hour-’, half-life 10.36 k 2.95 hours, v d  0.668 k 0.2 
L/kg, and TBC 0.05 f 0.02 Llkgihour.  The 
calculated dosing interval based on these values, 
and to obtain a desired peak gentamicin 
concentration of 6 mg/L with a dose of 2.5 mg/kg, 
was 14.55 hours. 
Statistical analysis of gentamicin pharmaco- 
kinetics for V-A versus V-V bypass and 0.6- versus 
0.8-m2 oxygenators did not yield any significant 
differences (p z 0.05) (Table 3). 
Discussion 
Gentamicin is commonly used for the treatment 
of neonatal sepsis, and its pharmacokinetics can 
be signif icantly altered during ECMO. We 
determined its pharmacokinetic values in 29 
infants of greater than 36 weeks gestational age 
receiving ECMO using two dif ferent bypass 
techniques and two different sizes of oxygenators. 
Although retrospective, our study has the 
advantage of larger sample size than other reports 
in the l iterature that evaluated gentamicin 
pharmacokinetics in term newborn infants. The 
drug’s volume of distribution in a population of neo- 
nates not on ECMO ranged from 0.5-0.6 L/kg7s8 
The mean Vd in our study population was similar- 
0.66 ? 0.2 L/kg. In addition, a 30% increase in 
membrane surface area (0.6-0.8 m2) did not affect 
vd, suggesting no apparent drug adsorption onto 
the oxygenator membrane. Our data are 
consistent with another report in which no change 
in serum gentamicin concentration was observed 
during an 8-hour sampling period after the 
administration of a 3-mg dose into the ECMO 
circuit, indicating that no substantial sequestration 
occurred.’2 We are confident comparing those 
findings to our results since the type of oxygenator 
used in both studies was the same. 
That group also reported a steady-state Vd and 
elimination half-life of 0.51 k 0.11 L/kg and 9.55 k 
4.38 hours, respectively, whereas other inves- 
tigators reported values of 0.78 L/kg and 8.7 hours, 
respect i~e1y.I~ In a group of 18 neonates the 
elimination half-life, vd,  and TBC were 10 hours, 
0.58 Ukg, and 0.042 L/kg/hour, re~pectively.’~ Our 
Vd was midway between these reported values. 
The elimination half-life of gentamicin in term 
newborns ranges from 5-6 hours, although 
substantial interindividual variations have been 
r e p ~ r t e d . ~ - ”  The mean half-l i fe in our study 
populat ion was 10.3 k 2.92 hours and was 
unusually long compared to term neonates not on 
ECMO. Since the drug is cleared almost entirely 
by the kidneys and since several of our patients 
had elevated serum creatinine concentrations, the 
increased half-life may have been a function of a 
reduced glomerular filtration rate in these acutely ill 
infants. Regardless of the presence of renal injury, 
however, decreased urine output with resulting 
oliguria or anuria frequently occurs in neonates on 
ECMO. 
The proposed causes for these changes are 
many. Dramatic changes in circulating profiles of 
arachidonic acid metabolites were observed in 
patients receiving ECMO, together with high 
plasma renin a ~ t i v i t y . ’ ~  Elevated blood 
concentrations of atrial natriuretic factor in these 
patients also have been reported.’‘ These 
physiologic changes may result in an alteration in 
total body water and thus a change in gentamicin 
volume of distribution. There is also a possible 
a 
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ECMO-related explanation for reduced gentamicin 
clearance. During V-A bypass, a decrease in 
pulsatile blood flow to the kidneys may occur. It is 
possible that the nonpulsatile blood flow could alter 
renal blood flow patterns and reduce the glomerular 
filtration rate, and therefore decrease gentamicin 
clearance. However, the overall effect of this 
change in flow does not appear to be substantial 
since (1) the difference in gentamicin half-life 
between the V-A bypass (10.04 i 2.45) and V-V 
bypass (10.75 f 3.43) infants is not significant, and 
(2) although urine output and sodium reabsorption 
decrease with nonpulsatile blood flow, no changes 
occur in glomerular filtration rate and total renal 
blood Two other groups also reported 
prolonged half- l i fe (mean 9.55 and 8.7 hrs, 
respectively) in infants on ECMO.”, l 3  
Analysis using the two-tailed Student’s t test 
indicates that the pharmacokinetics of gentamicin 
are not significantly different (p>0.05) for the two 
bypass techniques or sizes of oxygenators. It 
appears that factors other than nonpulsatile blood 
flow may be responsible for the drug’s prolonged 
half-life. Some possible alternative mechanisms 
include hypoxic-ischemic injury to the kidneys, shift 
in  intrarenal b lood flow, and distr ibution of 
gentamicin to compartments other than the central 
compartment. 
Since this was a retrospective study and 
comparisions were made not with a control group 
per se, but rather with l i terature-generated 
normative values, the potential for a type II error is 
large; however, calculation of the actual type II 
error would be inappropriate in a study of this 
nature. Comparision of gentamicin pharmaco- 
kinetics of the ECMO population to a more closely 
matched group of patients based on severity of 
i l lness may demonstrate a less dramatic 
difference. 
Based on the values determined in this study, a 
recommended initial dosage of gentamicin for 
neonates receiving ECMO is 2.5 mg/kg every 18 
hours. The dosing interval may be more variable 
and should be determined individually by 
monitoring serum drug concentrations over time. 
When ECMO is discontinued, the dosage may 
require readjustment due to large shifts in body 
water. 
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